This type of assay is referred to as Calibration Free Concentration Analysis, CFCA.
This type of assay is developed in close conjunction with the corresponding drug using the drug diagnostic codevelopment model.
This paper should have opened a new era for the sensible determination of DNA synthesis kinetics, however, by this time people were tired of and/or confused by this type of assay, and radiation biology shifted to new procedures.
Although there are many potential interfering factors in serum, rheumatoid factors (RFs), autoantibodies associated with rheumatoid arthritis (RA), are of particular concern in this type of assay.
The dose response curve of this type of assay had two remarkable features: (i) its ability to detect an output signal (i.e. bead number count) for very low Ag concentrations, and (ii) an output signal of the assay that was non-linear with respect to Ag concentration.
In addition, this type of assay could help unravel issues related to ESBL-producing isolates, among which false-negative or indeterminate results.
This type of assay has already proved it value for assessing drug-resistance determining regions in various bacteria (Deccache et al. 2011; Haanperä et al. 2005).
Future studies may incorporate this type of assay to provide a better understanding of the pharmacokinetic properties of herbal compounds.
For this type of assay, 96-well polystyrene microtiter plates (Greiner Bio-One, Frickenhausen, Germany) were employed.
However, with so few annotated genes and such poor coverage on the arrays, assessments using this type of assay would not be informative at this time.
In this type of assay, a fusion protein consisting of an RNA binding domain and GFP is tethered to an mRNA bearing the appropriate RNA binding sites [58].
